Cost-effectiveness of a new urinary biomarker-based risk score compared to standard of care in prostate cancer diagnostics - a decision analytical model.
Siebren DijkstraTim M GoversRianne J HendriksJack A SchalkenWim Van CriekingeLeander Van NesteJanneke P C GruttersJohn P Michiel SedelaarInge M van OortPublished in: BJU international (2017)
Based on the currently available evidence, the reduction of over diagnosis and overtreatment due to the use of the SelectMDx test in men with PSA levels of >3 ng/mL may lead to a reduction in total costs per patient and a gain in QALYs.